Ajai Chari, MD, details the accelerated FDA approval of talquetamab based on data from the MonumenTAL-1 study showing positive response rates in patients with advanced multiple myeloma. The study highlighted the latest efficacy results of every-two-week dosing, which demonstrated an advantageous option for patients treated with four or more lines of therapy and triple class exposure.
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More